Age related macular degeneration (ARMD) treatment using Lucentis

Request 1

ARMD and Lucentis

Does your Trust perform procedures for the treatment of ARMD using Lucentis?

Response 1

Yes

Request 2 

If yes, please provide the number of procedures carried out for financial years 2010/11 and to date in 2011/12.

Response 2

• 698 in 2010/11

• 428 in 2011/12 to date

Request 3

For the activity provided at question 2 how many different patients did this relate to?

Response 3 

• 172 in 2010/11

• 147 in 2011/12 to date

Request 4

What is the maximum number of procedures the Trust has performed on one individual patient irrespective of financial years?

Response 4

• 15 in 2010/11

• 8 in 2011/12 to date

• 21 over Apr10 to date

Request 5

Does the Trust obtain a refund from the drug company Novartis for patients receiving more than 14 procedures?

Response 5

Yes

Request 6

If yes is this refund passed on to the Commissioner?

Response 6 

Yes

Request 7

Is this procedure performed as a daycase or outpatient procedure?

Response 7

Day Case

Request 8

Does the Trust obtain payment for performing this procedure through Payment By Results or a locally agreed tariff with the Commissioner?

Response 8

Locally agreed.

Request 9

If Payment by Results what HRG is this coded to?

Response 9 

BZ23Z

CATARACTS

Request 1

Does the Trust perform cataract procedures?

Response 1

Yes

Request 2

If yes, please provide the number of procedures carried out for financial years 2010/11 and to date in 2011/12 split by HRG BZ02Z and BZ03Z

Response 2

Request 3 

Does the Trust follow a Best Practice pathway and obtain payment through Best Practice Tariffs for cataracts?

Response 3

The Trust does not follow the Best Practice pathway.